Purpose: We reviewed the literature to deter mine whether an analysis of published data could clarify the relationship between antiepileptic drug (AED) poly therapy and adverse affects (AE). We highlight the prob lems encountered.
A ntiepileptic drug (A E D ) pharmacotherapy is aim ed at reducing seizure frequency and severity without producing adverse effects (A E ). H owever, the reporting of A E in clinical trials lacks quantitative data because A E are often described in terms of frequency and rarely in terms of severity (1). A l though the incidence of A E is important, the degree to which they occur also determ ines the acceptability of individual A E D s. W hen quantitative data are pre sented, a com parison is com plicated because of the different rating scales used (2,3). T he risk of developm ent of chronic toxicity has been one of the argum ents against use of polyphar macy in epilepsy (4). M uch of this toxicity is believed to be directly related to the number of A E D s being consum ed, as the number of A E is often reduced after the number of A E D s is reduced
. Partly for this reason, monotherapy has long been advocated by leading epileptologists (7) .
H ow ever, the total A E D load of a multiple drug regimen rather than the number of A E D s may deter mine toxicity. High-level duotherapy is more likely to be associated with more A E than is the sam e com bination of drugs at low serum levels (8) . 
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571 epilepsy using this m ethod combined with a m ethod to quantify the incidence and severity of both seizures and AE. When the A E D load of both groups was equal, patients receiving polytherapy did not n eces sarily have higher toxicity than patients receiving monotherapy.
Because, the pharmacodynamic action o f seizure control does not necessarily correlate with n eu rotox icity, however, the D D D may not correlate w ell with AE. Instead of the D D D , ideally a defined toxic dose should be used in determining drug loads in relation to AE. Using serum levels instead of doses has an advantage in that average toxic serum levels have been published. Instead of the ATL, the average toxic level (A ToxL) must be substituted in the denom ina tor, thus creating an OSL/AToxL ratio. Serum levels, contrary to the P D D /D D D ratio, furthermore reflect differences in pharmacokinetics between different A E D s, although m etabolites and brain concentra tions are not accounted for.
In the present study, we surveyed the literature, using the P D D /D D D ratio and the O SL/AToxL ratio to evaluate the reporting of A E in relationship to A E D load. We placed special emphasis on articles reporting use of polytherapy in one of the treat ment groups. Table 1) and were analyzed statistically, by Pearson's correlation coefficient and th e ztransformation to test correlations between param e ters. Dice were thrown to select one observation ran domly per patient for statistical analysis. 
METHODS

We used the M edline program to screen the litera ture from 1974 to 1994, using the search com m ands [epilepsy], [adverse or side effects or cognitive or toxicity], and [combination therapy or add-on or dis continuation]. N ext, we made a further selection us ing the following requirements: (a) a multiple A E D regimen administered in one of the treatment groups of a trial, (b) mention of the dose or serum level of every prescribed A E D per patient or mean dose, respectively, serum level, and number of patients treated with each A E D per treatment group; and (c) mention of incidence and specification of A E per patient or treatment group.
Total drug load The D D D is based on the assumed average daily dose in its main indication in adults and is assigned by the World Health Organization for each drug. A n analogous ratio for A E D serum levels was developed in our institute. A ToxL per drug were assessed from literature data (10-13). The D D D and A T oxL were determined (
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RESULTS
Screening of the literature
Through the Medline search, w e retrieved 661 arti cles, o f which 118 were trial reports with a m ultiple drug regim en in at least one of the treatm ent groups. N ext, w e applied our requirements to select articles suitable for analysis. Three w ere not suitable because two of them compared differences in frequency o f adm inistration, e.g., a daily dose versus a three-tim es w eekly dose; the third reported a study of a new drug for which no information was available about the average effective dose. M ost articles w ere rejected for tw o reasons:
1
. E ighty studies in which new drugs, m ultiple drug regim ens, or a reduction in the num ber o f A E D s in these regimens w ere evaluated w ere rejected because the researchers did not provide data on doses or serum levels o f each drug or about the num ber of patients treated with the drug; a few representative exam ples are cited (1 4 -1 9 ). 2. T w enty papers were rejected because A E w ere
either not m entioned or w ere not adequately described. (O ne fourth of the articles w ere thus deficient). Seizure control was the on ly ou tcom e m easure in these cases (1 9 -2 1 ). F ifteen papers met the three requirem ents described in the M ethods section. In these, drug toxicity was evaluated by listing of subjective com plaints, by re p eated neurological exam inations, and/or by neuro psychological testing. Even in th ese articles, no sys tem atic comments were made regarding the severity o f the A E . We divided the selected articles into three groups: A , B, and C. Epilepsia, Vol. 38, No. 5, 1997 572 C. L. P. DECKERS ET AL. (22) (23) (24) (25) (26) . From the pubiished data, one measurement per patient was taken at random. ^Expressed in prescribed daily dose/defined daily dose. B: Adverse effects in relation to number of antiepileptic drugs in individual patients. Combined data from studies cited (22) (23) (24) (25) (26) . From the published data, the same measurement per patient was taken as described in A. Numbered dots indicate number of patients having the same coordinates. Fig. 1A . A lthough the correlation coefficients vary betw een the trials, a weak positive association be tw een these parameters does exist for the total group (r = 0.41). Fig. IB . We did not note a significant association betw een these parameters* total AED load or a higher O SL/AToxL ratio was associated with an increase in A E ( Table 2) . (Table 2) Table 3 Tables 1 and 2 . Trial designs, total drug loads and conclusions regarding cognitive changes as described in different reports. The changes in the cognitive functions are those observed after the second treatment was substituted for the first (i.e., VGB vs. placebo-the condition while receiving placebo). on neuropsychological tests than patients in treat ment groups with a lower drug load. 
A E and dose/serum levels reported per individual patient la five articles, the number and dose of all A E D s (but not serum levels) and A E were reported per patient (22-26). The total A E D load in relation to the number of A E in individual patients is shown in
The number o f A E D s in relation to the number of A E is shown in
A E and dose/serum levels reported per treatment group In seven articles, two treatments were compared and the number of A E effects and the average dose or serum level of every A E D was reported per treat m ent group (2 7 -3 3 ). We calculated the mean total A E D loads or O SL /A T oxL ratio per treatment group
Different neuropsychological tests were applied by the various researchers, which complicated a d etailed comparison. We calculated the mean total A E D lo a d or OSL/AToxL ratio per treatment group (T ab le 3). The tests the authors used are categorized according to cognitive functions and the results of the variou s trials in
. Thus, for example, decision m ak in g and visual scanning are categorized as com p on en ts of mental speed. Intellectual achievement was te ste d by arithmetic in three trials. Patients in treatm en t groups with higher drug loads or higher O S L /A T o x L ratios performed as well as or worse, but not b etter, TABLE 2, Trials in which number o f adverse effects was reported per treatment group
DISCUSSION
Critique of the literature
Methods of assessing A E , and in particular m eth ods of reporting about the incidence, leave much to be desired. Very few of the article we collected in this literature search satisfied the requirements for inclusion. Lack of information about the exact d os ages or serum levels of individual A E D s, or about the frequency of A E , or both, was particularly fre quent. The few articles selected would have been reduced even further if adequate quantification o f the severity of A E had been a requirement. This further compromises the comparability o f trials with regard to toxicity, because, if no use is m ade of vali dated scales, it is debatable whether one can w eigh the impact of A E if 10% of patients in one group and 20% in another group report dizziness. It is equally unclear how one can compare five cases of nausea in one group with five cases of drowsiness in another group without measuring how the health-related quality of life is affected. Several rating lists for scor ing A E quantitatively
Relation between number of AEDs, total drug load, and AE O nly group A articles allowed comparison of toxic ity in individual patients and could therefore be used to estim ate the correlation coefficient between toxic ity and drug load, respectively, and number of A E D s administered. C om parison of the articles in group A shows that the correlation between incidence of A E and drug load is slightly stronger than that between AE and num ber o f A E D s received, although both are weak and thus cannot be taken as proof. A n inherent weak ness of our analysis is that D D D are established only for the main indication of a drug, i.e., seizure control, and not for toxicity. Although correlations between serum levels and toxicity have been published, few articles retrieved in our study contained information about serum levels. This is regretable because the P D D /D D D ratio does not account for possible phar m acokinetic interactions. In group B and C articles, w e could not disentangle the cause of greater toxicity, which m ight just as well be due to the higher drug load as to use of multiple A E D s or to both. Although the inform ation we report does not yet permit conclu sions regarding the superiority of polytherapy to m o notherapy, it does remove one of the objections
against renewing the study of relative efficacy of m ono-and polytherapy, keeping the considerations of equal drug load in mind. That polytherapy may have its merits has been advocated, e.g., in hyperten sion and oncology therapy (36) (37) (38) . A prospective randomized double-blind study is in progress to ver ify the advantages or disadvantages of polytherapy in the treatment of epilepsy. N ot all the results we obtained were in accordance with the hypothesis of an association between total drug load and number of A E. O ne study in group C showed that elimination of phenytoin did have a beneficial effect on attention and concentration, whereas discontinuation of valproate or carbamazepine did not (34). This finding is in accord with reports that different A E D s often have different effects on cognitive functioning (39, 40) . Barbiturates have a greater impact on mental speed than do phenytoin, carbamazepine, and valproate (41). These differing drug effects em phasize the need for information about the quality of toxicity and its relationship to dosages. Qualitative and quantitative knowledge of drug-related toxicity is essential for accurate insight into the potential therapeutic window and the conse quent merits of a drug. U sing drug loads in relation ship to dosages allows comparison of single and/or multiple drug regimens and thus provides a better tool for interpretation and evaluation of differences in seizure control or toxicity. Having knowledge of both therapeutic and toxic serum levels, instead of dosages in evaluations of patients with difficult-totreat epilepsy receiving multiple drug regimens allows one to becom e cognizant of individual differ ences in m etabolism . The use of serum levels does increase the cost of therapeutic drug monitoring, however.
T he advantages of using methods to calculate total A E D load are illustrated by the study of McGuire et al. (35) , in which total drug loads in the vigabatrin add-on group and the placebo control group were high. A dding vigabatrin changed the drug load only by 20%. Therefore, given the premises of this method calculating total drug load, the patients in the placebo group were exposed to only a slightly less toxic total drug load than that of the add-on group, from which the effect of vigabatrin on cognitive function had to be evaluated. This em phasizes the importance of reporting doses or serum levels of concomitantly ad ministered drugs, particularly in parallel studies.
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